JP2005530736A - ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法 - Google Patents

ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法 Download PDF

Info

Publication number
JP2005530736A
JP2005530736A JP2003585730A JP2003585730A JP2005530736A JP 2005530736 A JP2005530736 A JP 2005530736A JP 2003585730 A JP2003585730 A JP 2003585730A JP 2003585730 A JP2003585730 A JP 2003585730A JP 2005530736 A JP2005530736 A JP 2005530736A
Authority
JP
Japan
Prior art keywords
optionally substituted
cvt
pharmaceutical composition
beta blocker
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530736A5 (https=
Inventor
ルイス・ベラルディネッリ
アービンダー・ダラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of JP2005530736A publication Critical patent/JP2005530736A/ja
Publication of JP2005530736A5 publication Critical patent/JP2005530736A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2003585730A 2002-04-18 2003-04-18 ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法 Pending JP2005530736A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376602P 2002-04-18 2002-04-18
PCT/US2003/012043 WO2003088978A1 (en) 2002-04-18 2003-04-18 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Publications (2)

Publication Number Publication Date
JP2005530736A true JP2005530736A (ja) 2005-10-13
JP2005530736A5 JP2005530736A5 (https=) 2006-06-01

Family

ID=29251078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585730A Pending JP2005530736A (ja) 2002-04-18 2003-04-18 ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法

Country Status (17)

Country Link
US (3) US7005425B2 (https=)
EP (1) EP1494685B1 (https=)
JP (1) JP2005530736A (https=)
KR (1) KR20040106354A (https=)
CN (2) CN1646142A (https=)
AT (1) ATE418991T1 (https=)
AU (1) AU2003235466C1 (https=)
CA (1) CA2482928A1 (https=)
DE (1) DE60325572D1 (https=)
ES (1) ES2318129T3 (https=)
IL (1) IL164652A0 (https=)
MX (1) MXPA04010285A (https=)
NO (1) NO20045005L (https=)
NZ (1) NZ536001A (https=)
RU (1) RU2332220C2 (https=)
WO (1) WO2003088978A1 (https=)
ZA (1) ZA200408411B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506486A (ja) * 2007-12-21 2011-03-03 エイオーピー オーファン ファーマスーティカルズ アクチエンゲゼルシャフト 医薬組成物
JP2013522323A (ja) * 2010-03-19 2013-06-13 イノテック ファーマシューティカルズ コーポレイション 眼内圧を下げるためのアデノシンＡ１受容体アゴニストと非選択的β−アドレナリン受容体遮断薬との組合せ組成物

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514515A (en) 1999-03-23 2003-11-28 Global Cardiac Solutions Pty L Organ arrest, protection and preservation using a potassium channel operator and/or adenosine receptor and a local anaesthetic
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
GB2436255B (en) * 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
EP1768991A1 (en) * 2004-07-12 2007-04-04 Cv Therapeutics, Inc. Process for the preparation of a1-adenosine receptor agonists
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) * 2004-08-30 2007-11-27 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP1802775B1 (en) 2004-09-14 2010-05-26 The Regents of the University of Colorado Method for treatment with bucindolol based on genetic targeting
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
AU2006345361B2 (en) 2006-05-29 2014-04-10 Hibernation Therapeutics, A Kf Llc Improved tissue maintenance
CA2692256C (en) 2006-07-25 2017-01-10 Hibernation Therapeutics Limited Trauma therapy
EP2173353B1 (en) 2007-03-02 2015-05-06 Hibernation Therapeutics, a KF LLC Composition including Adenosine and Lignocaine
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
GB0903299D0 (en) 2009-02-26 2009-04-08 Guys And St Thomas Nhs Foundat Composition and methods
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US20110039799A1 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
BR112016000809A2 (pt) 2013-07-17 2017-08-22 Hibernation Therapeuitics A Kf Llc Método para tratar infecção, sepsia e lesão
AU2014361813A1 (en) * 2013-12-13 2016-07-28 Ralph ANKENMAN Compositions and methods for treating dysregulated systems
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常
CN106370754B (zh) * 2016-11-07 2019-03-08 西安科技大学 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
KR102891439B1 (ko) 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10276991A (ja) * 1988-02-19 1998-10-20 Gensia Pharmaceut Inc 閉鎖系ドラッグデリバリーシステム
JP2000501426A (ja) * 1996-08-27 2000-02-08 スィーヴィー セラピューティクス インコーポレイテッド Ｎ▲上６▼ヘテロ環式置換アデノシン誘導体
JP2000510155A (ja) * 1996-06-28 2000-08-08 メルク エンド カンパニー インコーポレーテッド 医薬製剤
WO2001023399A1 (en) * 1999-09-30 2001-04-05 Pfizer Products Inc. Compounds for the treatment of ischemia
WO2001040246A1 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives
WO2002020024A1 (en) * 2000-09-08 2002-03-14 Cv Therapeutics, Inc. Purine ribosides as antiarrhythmics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
US6576620B2 (en) * 1999-12-03 2003-06-10 Cv Therapeutics, Inc. Method of identifying partial adenosine A1 receptor agonists
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10276991A (ja) * 1988-02-19 1998-10-20 Gensia Pharmaceut Inc 閉鎖系ドラッグデリバリーシステム
JP2000510155A (ja) * 1996-06-28 2000-08-08 メルク エンド カンパニー インコーポレーテッド 医薬製剤
JP2000501426A (ja) * 1996-08-27 2000-02-08 スィーヴィー セラピューティクス インコーポレイテッド Ｎ▲上６▼ヘテロ環式置換アデノシン誘導体
WO2001023399A1 (en) * 1999-09-30 2001-04-05 Pfizer Products Inc. Compounds for the treatment of ischemia
WO2001040246A1 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives
WO2002020024A1 (en) * 2000-09-08 2002-03-14 Cv Therapeutics, Inc. Purine ribosides as antiarrhythmics

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506486A (ja) * 2007-12-21 2011-03-03 エイオーピー オーファン ファーマスーティカルズ アクチエンゲゼルシャフト 医薬組成物
US10660964B2 (en) 2007-12-21 2020-05-26 Aop Orphan Pharmaceuticals Ag Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
US11517624B2 (en) 2007-12-21 2022-12-06 Aop Orphan Pharmaceuticals Gmbh Pharmaceutical composition for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists
JP2013522323A (ja) * 2010-03-19 2013-06-13 イノテック ファーマシューティカルズ コーポレイション 眼内圧を下げるためのアデノシンＡ１受容体アゴニストと非選択的β−アドレナリン受容体遮断薬との組合せ組成物

Also Published As

Publication number Publication date
ES2318129T3 (es) 2009-05-01
US20030216349A1 (en) 2003-11-20
MXPA04010285A (es) 2005-02-03
NZ536001A (en) 2006-05-26
US20090118221A1 (en) 2009-05-07
US7479485B2 (en) 2009-01-20
DE60325572D1 (de) 2009-02-12
AU2003235466A1 (en) 2003-11-03
RU2332220C2 (ru) 2008-08-27
NO20045005L (no) 2004-11-17
CN101385738A (zh) 2009-03-18
ATE418991T1 (de) 2009-01-15
CA2482928A1 (en) 2003-10-30
US20060052333A1 (en) 2006-03-09
US7005425B2 (en) 2006-02-28
EP1494685A1 (en) 2005-01-12
ZA200408411B (en) 2006-02-22
RU2004130826A (ru) 2005-05-10
AU2003235466C1 (en) 2008-03-20
WO2003088978A1 (en) 2003-10-30
KR20040106354A (ko) 2004-12-17
EP1494685B1 (en) 2008-12-31
IL164652A0 (en) 2005-12-18
CN1646142A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
JP2005530736A (ja) ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法
AU2003235466B2 (en) Method for treating arrhythmias
JP2010513565A (ja) Ａ１アデノシン受容体の部分アゴニストまたは完全アゴニストとしてのアデノシン誘導体
MXPA04008008A (es) Agonistas parciales y completos de receptores de adenosina a1.
US20090137520A1 (en) A1 adenosine receptor agonists
CA2421738C (en) Purine ribosides as antiarrhythmics
JP4596913B2 (ja) Ａ１アデノシン受容体の部分および完全アゴニスト
JP5204943B2 (ja) 末梢神経系の疾患の治療のためのピリミジンヌクレオチドの使用
AU2001292591A1 (en) Purine ribosides as antiarrhythmics
KR100518144B1 (ko) 항부정맥제로서의 퓨린 리보사이드
ZA200301684B (en) Purine ribosides as antiarrhythmics.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060404

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809